- Home
- MGIH vs EDSA Comparison
MGIH vs EDSA Comparison
Compare MGIH & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGIH
- EDSA
- Stock Information
- Founded
- MGIH 1978
- EDSA 2015
- Country
- MGIH Hong Kong
- EDSA Canada
- Employees
- MGIH N/A
- EDSA N/A
- Industry
- MGIH Publishing
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- MGIH Consumer Discretionary
- EDSA Health Care
- Exchange
- MGIH Nasdaq
- EDSA Nasdaq
- Market Cap
- MGIH 18.0M
- EDSA 17.2M
- IPO Year
- MGIH 2023
- EDSA N/A
- Fundamental
- Price
- MGIH $2.44
- EDSA $2.30
- Analyst Decision
- MGIH
- EDSA Strong Buy
- Analyst Count
- MGIH 0
- EDSA 2
- Target Price
- MGIH N/A
- EDSA $13.00
- AVG Volume (30 Days)
- MGIH 4.0M
- EDSA 12.0K
- Earning Date
- MGIH 10-29-2025
- EDSA 08-08-2025
- Dividend Yield
- MGIH N/A
- EDSA N/A
- EPS Growth
- MGIH N/A
- EDSA N/A
- EPS
- MGIH N/A
- EDSA N/A
- Revenue
- MGIH $28,866,993.00
- EDSA N/A
- Revenue This Year
- MGIH N/A
- EDSA N/A
- Revenue Next Year
- MGIH N/A
- EDSA N/A
- P/E Ratio
- MGIH N/A
- EDSA N/A
- Revenue Growth
- MGIH N/A
- EDSA N/A
- 52 Week Low
- MGIH $1.34
- EDSA $1.55
- 52 Week High
- MGIH $6.83
- EDSA $5.00
- Technical
- Relative Strength Index (RSI)
- MGIH 57.77
- EDSA 43.90
- Support Level
- MGIH $1.83
- EDSA $2.41
- Resistance Level
- MGIH $2.87
- EDSA $2.47
- Average True Range (ATR)
- MGIH 0.68
- EDSA 0.07
- MACD
- MGIH 0.05
- EDSA -0.02
- Stochastic Oscillator
- MGIH 27.05
- EDSA 0.00
About MGIH Millennium Group International Holdings Limited
Millennium Group International Holdings Ltd is a paper-based packaging solutions supplier. It offers paper-based inner and outer packaging products which can be broadly categorized into packaging products, Packaging products supply chain management solutions and corrugated products.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.